Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 14/20 | 0.69 |
| ▸ | UGCG | Q16739 | 1/20 | 0.46 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.44 |
| ▸ | TAOK3 | Q9H2K8 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1375631 | 1.00 | S1PR1 (0.69) | S1PR1UGCGTAOK1TAOK3ADRB1 | |
| SCHEMBL1373002 | 0.90 | S1PR1 (0.71) | S1PR1UGCGTAOK1TAOK3ADRB1 | |
| SCHEMBL1373005 | 0.90 | S1PR1 (0.71) | S1PR1UGCGTAOK1TAOK3ADRB1 | |
| SCHEMBL1372399 | 0.89 | S1PR1 (0.75) | S1PR1TAOK1TAOK3 | |
| SCHEMBL1372397 | 0.89 | S1PR1 (0.75) | S1PR1TAOK1TAOK3 | |
| SCHEMBL12044664 | 0.87 | S1PR1 (0.71) | S1PR1UGCGTAOK1TAOK3GPR34 | |
| SCHEMBL1375765 | 0.85 | S1PR1 (0.74) | S1PR1UGCG | |
| SCHEMBL1375767 | 0.85 | S1PR1 (0.74) | S1PR1UGCG | |
| SCHEMBL1376149 | 0.85 | S1PR1 (0.68) | S1PR1TAOK1TAOK3GPR34 | |
| SCHEMBL13392750 | 0.85 | S1PR1 (0.70) | S1PR1TAOK1TAOK3GPR34 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802692-B2 | Synergistic effects between sphingosine-1-phosphate receptor antagonists and antimicrotubule agents | EXELIXIS, INC. (US) | 2014-08-12 | — | — | US | claimed |
| CN-102245174-B | Synergistic effects between sphingosine-1-phosphate receptor antagonists and antimicrotubule agents | EXELIXIS INC | 2013-11-06 | — | — | CN | claimed |
| US-8802692-B2 | Synergistic effects between sphingosine-1-phosphate receptor antagonists and antimicrotubule agents | EXELIXIS, INC. (US) | 2014-08-12 | — | — | US | disclosed |
| US-8791102-B2 | Acetanilide sphingosine-1-phosphate receptor antagonists | EXELIXIS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| US-20110301188-A1 | Synergistic Effects Between Sphingosine-1-Phosphate Receptor Antagonists and Antimicrotubule Agents | EXELIXIS, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | EXELIXIS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| CN-102256944-A | Sphingosine-1-phosphate receptor antagonists | EXELIXIS INC | 2011-11-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301188-A1 | Synergistic Effects Between Sphingosine-1-Phosphate Receptor Antagonists and Antimicrotubule Agents | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885UGCG 823/4885TAOK1 1772/4885 |
| US-20110288076-A1 | Sphingosine-1-Phosphate Receptor Antagonists | S1PR1, S1PR2, S1PR3 | S1PR1 1/4885UGCG 147/4885TAOK1 2953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.